USS Investment Management Ltd reduced its holdings in Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 36.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 204,345 shares of the biotechnology company’s stock after selling 115,532 shares during the quarter. USS Investment Management Ltd owned 0.25% of Veracyte worth $9,411,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in Veracyte in the second quarter worth approximately $792,058,000. Dimensional Fund Advisors LP lifted its position in shares of Veracyte by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,881,090 shares of the biotechnology company’s stock valued at $92,787,000 after acquiring an additional 80,614 shares during the last quarter. William Blair Investment Management LLC boosted its stake in shares of Veracyte by 89.2% during the 3rd quarter. William Blair Investment Management LLC now owns 2,709,212 shares of the biotechnology company’s stock worth $124,732,000 after acquiring an additional 1,277,616 shares in the last quarter. First Trust Advisors LP boosted its stake in shares of Veracyte by 64.9% during the 1st quarter. First Trust Advisors LP now owns 2,117,046 shares of the biotechnology company’s stock worth $68,190,000 after acquiring an additional 833,543 shares in the last quarter. Finally, Congress Asset Management Co. bought a new stake in shares of Veracyte during the 3rd quarter worth $89,971,000.
Veracyte Stock Performance
NASDAQ VCYT opened at $25.09 on Friday. The firm’s 50 day moving average price is $40.41 and its two-hundred day moving average price is $42.10. Veracyte, Inc. has a twelve month low of $21.91 and a twelve month high of $60.91. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of 16.19 and a beta of 1.98.
Veracyte (NASDAQ:VCYT – Get Free Report) last released its earnings results on Wednesday, November 4th. The biotechnology company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.10. The company had revenue of $151.75 million during the quarter, compared to analyst estimates of $147.13 million. Veracyte had a return on equity of 8.99% and a net margin of 21.80%. The company’s revenue for the quarter was up 15.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.51 earnings per share. On average, research analysts forecast that Veracyte, Inc. will post 1.34 EPS for the current fiscal year.
Analysts Set New Price Targets
VCYT has been the topic of a number of recent analyst reports. Wolfe Research lowered Veracyte from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 6th. Stephens decreased their price target on Veracyte from $55.00 to $40.00 and set an “overweight” rating for the company in a research report on Wednesday, November 11th. Weiss Ratings upgraded Veracyte from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday. Wall Street Zen downgraded Veracyte from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Needham & Company LLC reduced their price objective on shares of Veracyte from $69.00 to $46.00 and set a “buy” rating for the company in a research note on Thursday, November 5th. Six investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $44.50.
Check Out Our Latest Report on Veracyte
Insider Buying and Selling at Veracyte
In other Veracyte news, Director Jens Holstein sold 7,500 shares of the stock in a transaction that occurred on Tuesday, October 27th. The shares were sold at an average price of $50.00, for a total value of $375,000.00. Following the completion of the sale, the director owned 27,471 shares in the company, valued at $1,373,550. This represents a 21.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John Leite sold 4,015 shares of Veracyte stock in a transaction on Monday, September 21st. The shares were sold at an average price of $40.00, for a total transaction of $160,600.00. Following the sale, the insider directly owned 124,329 shares of the company’s stock, valued at $4,973,160. This trade represents a 3.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 62,609 shares of company stock valued at $2,858,904 in the last 90 days. Corporate insiders own 1.60% of the company’s stock.
About Veracyte
Veracyte, Inc. is a genomic diagnostics company that develops tests to help clinicians diagnose disease and guide treatment decisions, with a focus on cancer and other complex conditions. Its tests analyze biological samples to provide information that can help distinguish between conditions and assess disease risk. The company’s portfolio includes Afirma for thyroid nodule assessment, Decipher for prostate cancer, Prosigna for breast cancer, and Percepta for lung cancer. Veracyte also offers Envisia, a genomic test that supports the diagnosis of idiopathic pulmonary fibrosis and other forms of interstitial lung disease.
Recommended Stories
- Five stocks we like better than Veracyte
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc. (NASDAQ:VCYT – Free Report).
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.
